Penpulimab
Penpulimab
Definition
A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, penpulimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.
Also known as AK 105, AK-105, AK105, Anike, Anti-PD-1 Monoclonal Antibody AK105, PENPULIMAB, Penpulimab-kcqx — per NCIT
Also identified as
- NCIT NCIT:C155879 per NCIT
- UNII IBS1BZ4E4I per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Nasopharyngeal carcinoma | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Chordate pharynx | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Craniocervical region | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Nasopharynx | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Neck | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Throat | may treat a disease of this organ | DERIVED · CC BY 4.0 |
5 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.